PROCUREMENT

        Inclusion Criteria:

          1. Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) AND suitable
             for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation
             of an identified eligible donor by a FACT accredited transplant center and with
             confirmation that the center plans to proceed with transplant if CLL-1.CAR treatment
             induces response they consider adequate to proceed to allogeneic HSCT

          2. CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or
             immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology
             laboratory

          3. Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults
             (≥18 yrs of age).

          4. Hgb ≥ 7.0 g/dL(can be transfused)

          5. Life expectancy greater than 12 wks

          6. If apheresis required to collect blood

               -  PT and APTT <1.5x ULN

               -  Serum Creatinine < 1.5 x ULN

               -  AST < 1.5 x ULN

          7. Informed consent

        Exclusion Criteria:

          1. Active infection (bacterial, fungal or viral) requiring ongoing treatment without
             improvement.

          2. Active infection with HIV or HTLV

          3. Active second cancer (except non-melanoma skin cancer or in situ breast cancer or
             cervix cancer)or other cancer treated ≤ 2 years prior to enrollment

          4. Ongoing treatment with immune suppression for prophylaxis or treatment of GVHD
             including high dose steroids (eg prednisone > 0.25mg/kg)

             -

        TREATMENT

        Inclusion Criteria:

          1. Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML). Patients
             with targetable mutations should have failed or be ineligible for targeted therapies
             (e.g. FLT3 inhibitors, IDH inhibitors, or anti-CD33 drug conjugate). AND patients
             should be suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant
             with confirmation of an identified eligible donor by a FACT accredited transplant
             center and with confirmation that the center plans to proceed with transplant if
             CLL-1.CAR treatment induces a response they consider adequate to proceed to allogeneic
             HSCT.

          2. CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or
             immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology
             laboratory

          3. Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults
             (≥18 yrs of age).

          4. AST/ALT less than 5 times the upper limit of normal

          5. Bilirubin less than 3 times the upper limit of normal

          6. Estimated GFR ≥ 60ml/min

          7. Pulse oximetry of > 92% on room air

          8. Karnofsky/Lansky ≥ 60

          9. Recovered from all acute toxic effects of prior chemotherapy at least one week before
             study entry and off systemic chemotherapy at least 2 weeks prior to study entry

         10. Available autologous transduced activated peripheral blood T-cell product with ≥ 20%
             expression of CLL-1.CAR.28z by flow cytometry

         11. Life expectancy > 12 weeks

         12. Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom

         13. Informed consent explained to, understood by, and signed by patient/guardian.
             Patient/guardian given copy of informed consent.

        Exclusion Criteria:

          1. Currently receiving any investigational agents or having received any tumor vaccines
             within the previous 6 weeks.

          2. History of hypersensitivity reactions to murine protein-containing products.

          3. Pregnant or lactating.

          4. Active infection with HIV or HTLV.

          5. Clinically significant bacterial, viral or fungal infection requiring ongoing
             antifungal therapy without improvement,.

          6. Cardiac criteria: Prolonged QTc with maximum interval as defined by age with ;
             Uncontrolled atrial fibrillation/flutter; Myocardial infarction within the last 6
             months; Cardiac echocardiography with LVSF<30% or LVEF<50% or clinically significant
             pericardial effusion; Cardiac dysfunction NYHA III or IV; CNS abnormalities: Presence
             of CNS disease defined as detectable cerebrospinal blast cells in a sample of CSF with
             ≥ 5 WBCs per mm3 or chloroma on imaging, History or presence of an underlying CNS
             disorder such as a seizure disorder requiring current use of antiepileptic
             medications, cerebrovascular ischemia/hemorrhage within prior 6 months, dementia,
             cerebellar disease, or any autoimmune disease with CNS involvement.

          7. Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28
             days

          8. Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 30
             days

          9. Acute GVHD ≥ Grade 2 or moderate to severe (formerly extensive) chronic GVHD

         10. Aministration of high dose steroids >1 mg/kg within the preceding 5 days or currently
             receiving > 0.25 mg/kg of Prednisone equivalent

         11. Hyperleukocytosis (WBC ≥50K) or rapidly progressive disease that in the estimation of
             the investigator would compromise the ability of the patient to complete the study.